These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bone Regulates Browning and Energy Metabolism Through Mature Osteoblast/Osteocyte PPARγ Expression. Brun J; Berthou F; Trajkovski M; Maechler P; Foti M; Bonnet N Diabetes; 2017 Oct; 66(10):2541-2554. PubMed ID: 28687706 [TBL] [Abstract][Full Text] [Related]
3. Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass. Kolli V; Stechschulte LA; Dowling AR; Rahman S; Czernik PJ; Lecka-Czernik B PLoS One; 2014; 9(5):e96323. PubMed ID: 24810249 [TBL] [Abstract][Full Text] [Related]
4. Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2). Stechschulte LA; Ge C; Hinds TD; Sanchez ER; Franceschi RT; Lecka-Czernik B J Biol Chem; 2016 Nov; 291(47):24475-24486. PubMed ID: 27687725 [TBL] [Abstract][Full Text] [Related]
5. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Patel JJ; Butters OR; Arnett TR Cell Biochem Funct; 2014 Jun; 32(4):368-77. PubMed ID: 24615887 [TBL] [Abstract][Full Text] [Related]
6. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Li M; Pan LC; Simmons HA; Li Y; Healy DR; Robinson BS; Ke HZ; Brown TA Bone; 2006 Oct; 39(4):796-806. PubMed ID: 16759917 [TBL] [Abstract][Full Text] [Related]
7. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Lazarenko OP; Rzonca SO; Suva LJ; Lecka-Czernik B Bone; 2006 Jan; 38(1):74-84. PubMed ID: 16137931 [TBL] [Abstract][Full Text] [Related]
8. S-nitrosoglutathione reductase-dependent PPARγ denitrosylation participates in MSC-derived adipogenesis and osteogenesis. Cao Y; Gomes SA; Rangel EB; Paulino EC; Fonseca TL; Li J; Teixeira MB; Gouveia CH; Bianco AC; Kapiloff MS; Balkan W; Hare JM J Clin Invest; 2015 Apr; 125(4):1679-91. PubMed ID: 25798618 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Okazaki R; Toriumi M; Fukumoto S; Miyamoto M; Fujita T; Tanaka K; Takeuchi Y Endocrinology; 1999 Nov; 140(11):5060-5. PubMed ID: 10537132 [TBL] [Abstract][Full Text] [Related]
10. Effect of the antidiabetic agent pioglitazone on bone metabolism in rats. Kanda J; Izumo N; Kobayashi Y; Onodera K; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H J Pharmacol Sci; 2017 Sep; 135(1):22-28. PubMed ID: 28928054 [TBL] [Abstract][Full Text] [Related]
11. Lentiviral delivery of PPARγ shRNA alters the balance of osteogenesis and adipogenesis, improving bone microarchitecture. James AW; Shen J; Khadarian K; Pang S; Chung G; Goyal R; Asatrian G; Velasco O; Kim J; Zhang X; Ting K; Soo C Tissue Eng Part A; 2014 Oct; 20(19-20):2699-710. PubMed ID: 24785569 [TBL] [Abstract][Full Text] [Related]
12. Osteoblast-targeted overexpression of PPARγ inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice. Cho SW; Yang JY; Her SJ; Choi HJ; Jung JY; Sun HJ; An JH; Cho HY; Kim SW; Park KS; Kim SY; Baek WY; Kim JE; Yim M; Shin CS J Bone Miner Res; 2011 Aug; 26(8):1939-52. PubMed ID: 21351141 [TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Ali AA; Weinstein RS; Stewart SA; Parfitt AM; Manolagas SC; Jilka RL Endocrinology; 2005 Mar; 146(3):1226-35. PubMed ID: 15591153 [TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α. Takano M; Otsuka F; Matsumoto Y; Inagaki K; Takeda M; Nakamura E; Tsukamoto N; Miyoshi T; Sada KE; Makino H Mol Cell Endocrinol; 2012 Jan; 348(1):224-32. PubMed ID: 21888945 [TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma regulates bone remodeling after midpalatal suture expansion in mice. Wu J; Ru N; Li S Int J Oral Maxillofac Implants; 2015; 30(6):1423-30. PubMed ID: 26478981 [TBL] [Abstract][Full Text] [Related]
17. PPAR gamma: ally and foe in bone metabolism. Wahli W Cell Metab; 2008 Mar; 7(3):188-90. PubMed ID: 18316021 [TBL] [Abstract][Full Text] [Related]
18. Transgenic overexpression of tartrate-resistant acid phosphatase is associated with induction of osteoblast gene expression and increased cortical bone mineral content and density. Gradin P; Hollberg K; Cassady AI; Lång P; Andersson G Cells Tissues Organs; 2012; 196(1):68-81. PubMed ID: 22248481 [TBL] [Abstract][Full Text] [Related]
19. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis. Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822 [TBL] [Abstract][Full Text] [Related]
20. Regulatory Effect of Osteocytes on Extramedullary and Bone Marrow Adipose Tissue Development and Function. Lecka-Czernik B; Khan MP; Letson J; Baroi S; Chougule A Curr Osteoporos Rep; 2024 Jun; 22(3):301-307. PubMed ID: 38625510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]